Early Life
Andreas Strüngmann was born in 1950 in Mülheim an der Ruhr, Germany. He earned a medical degree from the University at Buffalo. Together with his identical twin brother, Thomas, he joined their father's pharmaceutical company, Durachemie, gaining industry experience.
Rise to Success
In 1986, the Strüngmann brothers co-founded Hexal AG, a generic drug manufacturer, which grew to become Germany's second-largest. They sold Hexal and their stake in U.S. Eon Labs to Novartis in 2005 for $7.5 billion. After the sale of Hexal, they shifted their focus to biotech and healthcare investments, establishing investment firms like Santo Holding and Athos Service. In 2008, they invested in BioNTech, which later collaborated with Pfizer to produce a successful COVID-19 vaccine.
Key Business Strategies
The Strüngmanns' success stems from strategic investments in pharmaceuticals and biotechnology. They identify and support high-potential ventures. Their early investment in BioNTech and the development of the COVID-19 vaccine significantly boosted their wealth. They focus on long-term investments and innovation, especially in the healthcare sector.
Philanthropy
Andreas and his wife established the Andreas and Susan Struengmann Foundation in 2007 to support educational initiatives. They also founded the Ernst Strüngmann Institute for neuroscience research.
